TGFBR2 and melanoma: Combined in vitro and in vivo screening revealed the most promising CSR, such as TGFBR2-4-1BB, which enhanced the anti-tumor function of NY-ESO-1 TCR+ T cells in a human melanoma xenograft mouse model.